COMPASS THERAPEUTICS INC.
NASDAQ: CMPX (Compass Therapeutics, Inc.)
Last update: 3 hours ago5.65
-0.13 (-2.25%)
| Previous Close | 5.78 |
| Open | 5.73 |
| Volume | 3,677,758 |
| Avg. Volume (3M) | 2,125,421 |
| Market Cap | 1,004,920,832 |
| Price / Sales | 269.28 |
| Price / Book | 5.33 |
| 52 Weeks Range | |
| Earnings Date | 2 Mar 2026 |
| Operating Margin (TTM) | -7,273.06% |
| Diluted EPS (TTM) | -0.400 |
| Total Debt/Equity (MRQ) | 5.79% |
| Current Ratio (MRQ) | 8.33 |
| Operating Cash Flow (TTM) | -44.17 M |
| Levered Free Cash Flow (TTM) | -25.01 M |
| Return on Assets (TTM) | -26.41% |
| Return on Equity (TTM) | -41.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Compass Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 14.16% |
| % Held by Institutions | 67.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tang Capital Management Llc | 31 Dec 2025 | 16,790,809 |
| Suvretta Capital Management, Llc | 31 Dec 2025 | 14,182,379 |
| Vivo Capital, Llc | 31 Dec 2025 | 9,545,466 |
| Enavate Sciences Gp, Llc | 31 Dec 2025 | 7,788,150 |
| Blackstone Inc. | 31 Dec 2025 | 6,126,182 |
| Rock Springs Capital Management Lp | 31 Dec 2025 | 3,927,202 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 3,606,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (D. Boral Capital, 430.97%) | Buy |
| Median | 10.00 (76.99%) | |
| Low | 10.00 (Canaccord Genuity, 76.99%) | Buy |
| 10.00 (Citizens, 76.99%) | Buy | |
| Average | 16.67 (195.04%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 5.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 06 Jan 2026 | 30.00 (430.97%) | Buy | 4.91 |
| Canaccord Genuity | 03 Dec 2025 | 10.00 (76.99%) | Buy | 5.28 |
| Citizens | 03 Dec 2025 | 10.00 (76.99%) | Buy | 5.28 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jan 2026 | Announcement | Compass Therapeutics Provides Corporate Update |
| 05 Jan 2026 | Announcement | Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Jan 2026 | Announcement | Compass Therapeutics Announces Key Leadership Appointments |
| 17 Dec 2025 | Announcement | Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |